Do semaglutide tablets help with weight loss?

What the trial results actually mean for your decision

The clearest place to start is the clinical evidence. The OASIS 4 trial enrolled 307 adults living with obesity or overweight plus at least one weight-related condition, with no type 2 diabetes, and ran for 64 weeks. Participants who took oral semaglutide lost an average of 13.6% of body weight, compared with 2.4% on placebo, both groups made lifestyle changes throughout. Among those who stayed fully on track with their doses, weight loss reached roughly 17%, though that figure applies specifically to full adherers, not to the trial population as a whole.

Those numbers matter because they set realistic expectations. A 13–17% reduction is clinically meaningful: research consistently links that range of weight loss to improvements in blood pressure, cholesterol and blood-sugar regulation. The NHS semaglutide medicines page notes that treatment works alongside, not instead of, dietary changes and increased activity. Weight lost during the trial was achieved with both.

The decision question here is not simply "does it work" but "does the level of effect suit what I am trying to achieve, and am I likely to adhere to a daily tablet routine?" If you are uncertain, this overview of whether semaglutide tablets are a good fit explores those questions in more depth.

Who the licence covers, and who it does not

The MHRA approved Wegovy tablets on 11 June 2026 for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. As of summer 2026, the tablets are available only through a private prescription; a NICE appraisal would be needed before NHS commissioning could begin.

The licence does not cover under-18s, and the tablets are not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. Certain conditions (including a personal or family history of medullary thyroid carcinoma) require a prescriber to assess suitability carefully before proceeding. BMI alone does not determine approval; a prescriber looks at the whole clinical picture.

One thing worth knowing: Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg strengths, entirely different from the Wegovy weight-loss tablet schedule. If you have seen references to a 7 mg semaglutide tablet in a weight-loss context, that page explains the distinction clearly, because the Rybelsus doses are not interchangeable with the Wegovy weight-loss doses.

Tablet versus injection: the practical difference

For many people, the most immediate question is not mechanism but routine. The injection is once weekly; the tablet is once daily. The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, then you wait at least 30 minutes before eating, drinking coffee or taking other oral medicines. That pause (before the kettle gets used for anything else) is the non-negotiable part of the daily habit.

On the other side of the ledger, the tablets need no refrigeration. That matters if you travel frequently, dislike injections, or simply find a tablet easier to manage than a pen device. The full Wegovy pill guide sets out the complete dosing schedule and how the escalation from 1.5 mg to 25 mg works in practice. The injection version and what it involves is covered on the Wegovy weight-loss tablets page if you want to compare both formats side by side.

Neither format is objectively superior; the right one depends on your lifestyle, any clinical factors your prescriber identifies, and your own preference. That conversation is exactly what a clinical consultation is for.

Cost context and how to find out if you are eligible

Because oral semaglutide for weight loss is newly approved and available only privately, pricing is still settling across providers. A factual guide to what private weight-loss treatment costs (and what to expect those costs to include) is on the Wegovy tablet pricing page. As a general principle, a legitimate price from a regulated UK pharmacy will include the prescription and clinical assessment; any listing that appears to offer these medicines without those elements should be treated with caution.

If you want to understand the broader landscape of injectable and tablet options before deciding, the weight-loss treatments overview sets out what is licensed in the UK and how the different medicines compare. For a closer look at how the new oral option fits into that picture, the new semaglutide pill page covers the approval story and what it means for people who previously ruled out injections.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated triage system. Our clinical team page gives you a sense of who reviews prescriptions here. If you have questions before you begin, our FAQs cover the most common ones, and the team is reachable via the contact page seven days a week.